A Phase 1, Open Label Study In Healthy Subjects To Investigate The Pharmacokinetics Of Pf 06865571 Following Single Oral Administration Of Immediate And Modified Release Tablets Compared To Immediate Release Oral Suspension Under Fed Conditions
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- Maximum Observed Plasma Concentration (Cmax) for PF-06865571
研究概览
简要总结
An open-label study to understand the effect of different modified release and immediate release formulations on plasma PF-06865571 concentrations after single oral administration under fed conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Basic Science
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy males and female of non-childbearing potential
- •Age of 18-55, inclusive
- •Body Mass Index 17.5 to 30.5 kg/m2, inclusive
- •Body weight >50 kg
- •Not on any prescription or non-prescription drugs within 7 days or 5 half-lives prior to first dose.
排除标准
- •Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- •Any condition possibly affecting drug absorption (eg, gastrectomy).
- •A positive urine drug test.
- •History of regular alcohol consumption exceeding 14 drinks/week for female subjects or 21 drinks/week for male subjects (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor) within 6 months before screening.
- •Treatment with an investigational drug within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of investigational product (whichever is longer).
- •Screening supine BP >=140 mm Hg (systolic) or >= 90 mm Hg (diastolic), following at least 5 minutes of supine rest.
- •Screening supine 12 lead ECG demonstrating a corrected QT (QTc) interval >450 msec or a QRS interval >120 msec.
- •Subjects with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level >=1.25 × upper limit of normal (ULN);
- •Total bilirubin level >=1.5 × ULN; subjects with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is =<ULN.
- •Fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.
- •Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
- •History of sensitivity to heparin or heparin induced thrombocytopenia only if heparin is used to flush any intravenous catheters in the study.
- •History of human immunodeficiency virus (HIV), hepatitis B, or hepatitis C; positive testing for HIV, hepatitis B surface antigen (HepBsAg), hepatitis B core antibody (HepBcAb), or hepatitis C antibody (HCVAb).
- •Unwilling or unable to comply with Lifestyle Requirements in the protocol
- •Subjects who are investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
- •Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
- •Subjects who have previously participated in prior studies with PF 06865571 as the investigational product.
研究组 & 干预措施
PF-06865571
Treatment
干预措施: PF-06865571 Immediate release suspension (Drug)
PF-06865571
Treatment
干预措施: PF-06865571 Slow release MR tablets (Drug)
PF-06865571
Treatment
干预措施: PF-06865571 Fast release MR tablets (Drug)
PF-06865571
Treatment
干预措施: PF-06865571 Immediate release tablets (Drug)
结局指标
主要结局
Maximum Observed Plasma Concentration (Cmax) for PF-06865571
时间窗: 0,0.5,1,2,3,4,6,8,12,24,36,48 hours post dose in each period
Time to Reach Maximum Observed Concentration for PF-06865571
时间窗: 0,0.5,1,2,3,4,6,8,12,24,36,48 hours post dose in each period
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for PF-06865571
时间窗: 0,0.5,1,2,3,4,6,8,12,24,36,48 hours post dose in each period
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Area Under the Curve From Time Zero to Extrapolated Infinite Time for PF-06865571
时间窗: 0,0.5,1,2,3,4,6,8,12,24,36,48 hours post dose in each period
AUC (0-infinity)= Area under the plasma concentration versus time curve (AUC) from time zero (pre-dose) to extrapolated infinite time (0-infinity). It is obtained from AUC (0-t) plus AUC (t-infinity).
Plasma Decay Half-Life (t1/2) for PF-06865571
时间窗: 0,0.5,1,2,3,4,6,8,12,24,36,48 hours post dose in each period
Plasma Decay Half-Life (t1/2)
次要结局
- Number of subjects with adverse events (AEs)(Baseline up to 35 days after last dose)
- Number of subjects with laboratory tests findings of potential clinical importance(Baseline (Day 0) up to 48 hours after last dose of study medication)
- Number of subjects with electrocardiogram (ECG) findings of potential clinical importance(Baseline (Day 0) up to 48 hours after last dose of study medication)
- Number of subjects with vital signs findings of potential clinical importance(Baseline (Day 0) up to 48 hours after last dose of study medication)